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postprandial AUI response to FFB (P = 1.88E-06), respec-
tively. We sought to replicate the association for SIPA1L2 in 
the Heredity and Phenotype Intervention (HAPI) Heart 
Study, which included a high-fat meal challenge but not FFB 
treatment. The associated rare variants in GOLDN were not 
observed in the HAPI Heart study, and thus the gene-based 
result was not replicated. For functional validation, we found 
that gene transcript level of SIPA1L2 is associated with tri-
glyceride postprandial AUI (P < 0.05) in GOLDN.  Our 
study suggests unique genetic mechanisms contributing to 
the lipid response to the high-fat meal challenge and FFB 
therapy.—Geng, X., M. R. Irvin, B. Hidalgo, S. Aslibekyan, 
V. Srinivasasainagendra, P. An, A. C. Frazier-Wood, H. K. 
Tiwari, T. Dave, K. Ryan, J. M. Ordovas, R. J. Straka, M. F. 
Feitosa, P. N. Hopkins, I. Borecki, M. A. Province, B. D. 
Mitchell, D. K. Arnett, and D. Zhi. An exome-wide sequenc-
ing study of lipid response to high-fat meal and fenofibrate 
in Caucasians from the GOLDN cohort. J. Lipid Res. 2018. 
59: 722–729.
Abstract Our understanding of genetic influences on the 
response of lipids to specific interventions is limited. In this 
study, we sought to elucidate effects of rare genetic variants 
on lipid response to a high-fat meal challenge and fenofi-
brate (FFB) therapy in the Genetics of Lipid Lowering Drugs 
and Diet Network (GOLDN) cohort using an exome-wide 
sequencing-based association study. Our results showed that 
the rare coding variants in ITGA7, SIPA1L2, and CEP72 are 
significantly associated with fasting LDL cholesterol re-
sponse to FFB (P = 1.24E-07), triglyceride postprandial area 
under the increase (AUI) (P = 2.31E-06), and triglyceride 
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Dyslipidemia, defined as abnormal levels of lipids 
and/or lipoproteins in the blood (1), is a critical modi-
fiable risk factor for chronic diseases, accounting for 
almost half of the population attributable risk for ad-
verse cardiovascular events (2). Circulating lipid levels 
are influenced by both environment (e.g., diet, smok-
ing, and prescription drugs) and genetic variation; twin 
studies estimate the genetic contribution to explain 
60% of phenotypic variation (3). Until recently (4), 
findings from genome-wide association studies have ac-
counted for about 12% of blood lipid variance. The pro-
portion of unexplained variance (48%) could be 
lessened with the inclusion of rare variant analyses, il-
lustrating the important role of the low-frequency poly-
morphisms in the genetic architecture of lipid traits 
(5). These rare variants, which were not covered by 
previous genome-wide association studies but contrib-
ute to lipid traits, could be located in coding regions, as 
well as introns, untranslated regions, and intergene 
regions.
To date, such high-resolution genetic investigations of 
lipids have focused only on fasting phenotypes, while 
knowledge of genetic determinants of lipid response to in-
terventions remains limited. The Genetics of Lipid Lower-
ing Drugs and Diet Network (GOLDN) study cohort 
provides a unique opportunity to study the effects of rare 
genetic variants on response to two interventions, a high-
fat meal (postprandial lipemia; PPL) and fenofibrate (FFB) 
treatment, due to its carefully controlled intervention by 
standardizing the environmental perturbation. The high-
fat meal intervention provides a unique and impactful way 
to study dyslipidemia in a dynamic test, not only because 
humans spend most of their waking hours in the postpran-
dial state, but also because of the high fat content of West-
ern diets. Furthermore, an elevated postprandial lipid 
response, followed by delayed clearance, has been shown 
to predict future risk of cardiovascular disease (6). Addi-
tionally, the second GOLDN intervention(the 3 week treat-
ment with micronized FFB)creates an opportunity for 
pharmacogenomic discovery and a deeper understanding 
of individual variation to lipid-lowering drugs (7). Prior 
studies in GOLDN have scanned common variants to iden-
tify multiple promising determinants of response to both 
interventions (8–10); however, they were conducted prior 
to the availability of high-resolution genomic data. To aug-
ment the discoveries from the Genome-Wide Association 
Study (GWAS), account for further missing heritability, 
and identify additional functional loci contributing to vari-
ation in lipid response to a high-fat meal and treatment 
with FFB, we performed an exome-wide sequencing study 
in 894 European Americans from the GOLDN study. We 
sought to replicate the PPL result using the Heredity and 
Phenotype Intervention (HAPI) Heart Study, which included 
a high-fat meal challenge but not FFB treatment. In addi-
tion, we sought to validate the associations for our findings 
using DNA methylation and RNA-sequencing (RNA-Seq) 
data previously collected in GOLDN.
METHODS
Study population
GOLDN (clinicaltrials.gov NCT00083369) was designed to 
characterize genetic factors that determine response of lipids to 
two environmental interventions: a 3 week FFB treatment and a 
high-fat meal challenge (8, 9, 11). Only Caucasian families with at 
least two siblings were included. Participants were asked to discon-
tinue any lipid-lowering agents (pharmaceuticals or nutraceuti-
cals) for at least 4 weeks prior to the initial visit. GOLDN recruited 
and sequenced 894 subjects from 186 families recruited at two 
centers (Minneapolis, MN, and Salt Lake City, UT). Of the 
894 subjects, 810 participants participated in the high-fat meal 
intervention. After that, 797 GOLDN participants received daily 
treatment with 160 mg micronized FFB for 3 weeks and were fol-
lowed for treatment response. Finally, 715 participants partici-
pated in another high-fat meal intervention to investigate lipid 
response to the high-fat meal while treated with FFB. The popula-
tion size indicates that we have statistical power ranging from 0.5 
for h2locus= 0.02 to 1.00 for h
2
locus= 0.05 or above. Our study has 
been approved by the committee for the protection of human 
subjects in the University of Texas Health Science Center at Hous-
ton and the other institutions, and it abides by the Declaration 
of Helsinki principles. Informed consent was obtained from the 
human subjects.
Clinical measurements
Clinical lipids including HDL cholesterol (HDL-C), LDL cho-
lesterol (LDL-C), and triglycerides (TGs) were measured in this 
study. TG was measured by using the glycerol-blanked enzymatic 
method on the Roche COBAS FARA centrifugal analyzer (Roche 
Diagnostics Corporation) (10). HDL-C was measured by using the 
same procedure as TG after precipitation of non-HDL cholesterol 
with magnesium/dextran. LDL-C was measured by using a homo-
geneous direct method (LDL Direct Liquid Select™ Cholesterol 
Reagent; Equal Diagnostics) on a Hitachi 911 Automatic Ana-
lyzer. The FFB treatment and the high-fat meal intervention in 
GOLDN have been described previously (10, 12). During the 
high-fat meal intervention, blood was collected three times for 
pre- and post-FFB treatment, respectively: draw 1 (fasting) imme-
diately prior to the meal (0 h), draw 2 approximately 3.5 h after 
the meal, and draw 3 approximately 6 h after the meal. We ex-
cluded 14 individuals in pre-FFB and 20 individuals in post-FFB 
from our postprandial analyses who did not follow the protocol 
schedule, which resulted in large drawtime deviations (>1 h). 
HDL- and LDL-C were only assessed at draw 1 both before and 
after FFB treatment. TG was assessed at each blood draw, which 
allowed an analysis of response to the high-fat meal and FFB, and 
change in high-fat meal response with FFB.
Library preparation
Genomic DNA from peripheral blood nucleated cells was 
extracted by using QIAmp 96 DNA Blood Kits (Qiagen, Hilden, 
Germany). The integrity and yield of native genomic DNA was 
verified by a PicoGreen assay for quantitation (Invitrogen, Life 
Technologies, Carlsbad, CA) and run on a 0.8% agarose gel for 
quality control (QC). Illumina paired-end small-fragment libraries 
were constructed according to the manufacturer’s recommenda-
tions (Illumina Inc., San Diego, CA) with the following excep-
tions: 1) 500–1,000 ng of native genomic DNA was fragmented by 
using the Covaris E220 DNA Sonicator (Covaris, Inc., Woburn, 
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MA) to a size range between 100 and 400 bp; 2) Illumina adaptor-
ligated library fragments were amplified in four 50 µl PCR reac-
tions for 18 cycles; and 3) solid-phase reversible immobilization 
bead clean-up was used for enzymatic purification throughout the 
library process, as well as for final library size selection targeting 
300 to 500 bp fragments.
Exome capture and sequencing
Libraries were pooled precapture and hybridized to Nimble-
Gen SeqCap EZ Human VCRome Library kits (Roche Nimble-
Gen, Madison, WI) according to the manufacturer’s protocol. 
The concentration of each captured library was determined 
through KAPA quantitative PCR (Kapa Biosystems, Inc., Woburn, 
MA) according to the manufacturer’s protocol to produce cluster 
counts appropriate for the Illumina HiSeq 2000 platform. The 
libraries were run on a HiSeq 2000 V3 2×101-bp sequencing run 
according to manufacturer recommendations.
Sequence alignment
Illumina sequencing data in FASTQ format were aligned to 
the GRCh37-lite reference sequence by using BWA (13) (version 
0.5.9) with the parameters: -t 4 -q 5. Duplicates were marked in 
each Binary Alignment/Map (BAM) file by using Picard (http://
broadinstitute.github.io/picard/) (version 1.46). If a sample was 
sequenced across multiple lanes, the aligned BAM files were 
merged by using Picard (version 1.46).
Variant calling, variant call file creation, and annotation
Each BAM file was sorted with potential PCR duplications 
removed by using SAMtools (version 1.2.1) (14, 15). Subject-level 
single nucleotide variants (SNVs) were called by using the Atlas-
SNP2 application with a variant call file (VCF) created for each 
subject (16). Furthermore, for each chromosome, a population-
level VCF was created by using the SAMtools mpileup/BCFtools 
(13, 14), where the SNVs at all the discovered sites were called and 
backfilled in multiple samples by using the original BAMs from all 
the GOLDN subjects. Finally, a combined project-level VCF was 
created through merging all the 25 population-level VCF files 
(chromosomes 1–22, X, Y, and mitochondrial) by using the 
GATK-CatVariants (version 3.5) (17–19). Only biallelic mutations 
were kept after filtered by using VCFtools (15). For the genotype-
level QC, genotypes with read depth <20 or genotyping quality 
<30 were excluded. For the variant-level QC, the mutations were 
filtered out if their missing rate was >5%. The project-level VCF 
was further annotated by using ANNOVAR (20) according to 
hg19 genome assembly/dbSNP (version 138). Four classes of 
functional variants (splicing, nonsynonymous, stop-loss, and stop-
gain) on chromosomes 1–22 were used for association tests (21).
Sample-level QC
Target region breadth by depth for each sample was evaluated 
by using RefCov (http://gmt.genome.wustl.edu/packages/refcov/) 
v0.3 with a Browser Extensible Data file of target regions provided 
by the exome kit manufacturer. We required that >70% of target 
bases were covered at >20x; samples below that threshold received 
additional (top-up) sequencing.
To confirm sample purity and identity, we compared high-den-
sity SNP array genotypes (9) (Illumina OmniExpress) to the SNV 
calls obtained from the sequencing data by using SAMtools (15) 
version r963, and required >90% genotype concordance to pass a 
sample. No samples were excluded due to low concordance.
Phenotype definition
All the lipid values were natural log-transformed to achieve 
normality of residuals. Baseline was defined as the value at 0 h 
(i.e., fasting) at the pre-FFB visit. Fasting-level response to FFB was 
defined as the difference of log-transformed lipid plasma concen-
trations at draw 1 between post- and pre-FFB. Three TG pre-FFB 
postprandial phenotypes were assessed, including uptake, clear-
ance, and area under the increase (AUI). TG values at each blood 
draw were natural log-transformed first. Uptake and clearance 
were defined as the slope of the line of TG response from draw 1 
to draw 2 and from draw 2 to draw 3, respectively. Next, AUI was 
calculated with the transformed value by using the trapezoid rule. 
Because draw time deviations from protocol could result in proce-
dural errors in AUI measurement, TG values at 6 h were estimated 
by using the values and draw times of draws 2 and 3 by linear 
extrapolation. AUI was calculated with the measured values at 
draws 1 and 2, and the estimated value at 6 h to mitigate the effect 
caused by draw time deviation. The postprandial phenotype re-
sponse to FFB were the change of PPL phenotype before and after 
FFB treatment. These phenotypes included uptake response to 
FFB, clearance response to FFB, and AUI response to FFB.
Statistical analysis
Genetic associations were assessed by using linear mixed mod-
els using RAREMETALWORKER and RAREMETAL (version 
4.13.6) (22, 23). We considered a minimal model and a fully 
adjusted model. In the minimal model, all the associations were 
adjusted for sex, age, age2, age3, and recruiting center as fixed ef-
fects (24, 25). For the FFB analyses, an additional variable measur-
ing the number of pills taken per day (to adjust for compliance) 
was included as a covariate. In addition, a kinship coefficient con-
sidered as a random effect was used to adjust for family related-
ness. In the full model, apart from those covariates included in 
minimal models, additional related lipid levels were included as 
covariates. For the fasting-level response to FFB and pre-FFB post-
prandial AUI and uptake, respective baseline levels were included 
as covariates. For the pre-FFB postprandial clearance phenotype, 
draw 2 lipid level was used as a covariate. For the three postpran-
dial lipid level response to FFB, their corresponding pre-FFB 
treatment level and fasting-level response to FFB were included as 
covariates (supplemental Table S1).
For gene-based analyses, sequence kernel association test 
(SKAT), simple burden test, Madsen and Browning weighted bur-
den test (MB), and variable threshold test were utilized with mul-
tiple frequency thresholds for variant inclusion (MAF < 5% and 
1%) (26–28).
Bonferroni corrections were used for both single-variant and 
gene-based associations. The significant signals were filtered out if 
they were driven by variants carried by less than three individuals 
or one single family.
Replication
We sought to replicate our associations for TG postprandial 
phenotypes using the HAPI Heart Study (29), in which postpran-
dial TG levels were measured at 0, 1, 2, 3, 4, and 6 h after 770 Old 
Order Amish participants underwent a high-fat feeding interven-
tion identical to the one used in GOLDN. More study procedure 
details can be found in previous reports (10, 29). HAPI Heart 
Study participants were genotyped as part of the Trans-Omics for 
Precision Medicine effort using whole-genome sequencing meth-
ods. TG postprandial phenotypes were defined in the HAPI Heart 
Study similarly as described above in GOLDN but calculated with 
measured values at 0, 3, and 6 h. Demographic and clinical char-
acteristics of the HAPI Heart Study are listed in supplemental 
Table S2.
The association of GOLDN top hits in the replication cohort 
was tested by using RAREMETALWORKER with an identical 
model to GOLDN. Next, we also performed a joint meta-analysis of 
GOLDN top hits across all participating cohorts using RAREMETAL.
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Functional validation
We sought to validate the associations for our findings using 
DNA methylation and RNA-Seq data previously collected in 
GOLDN. CpG site methylation was quantified by using the Illu-
mina (San Diego, CA) Infinium Human Methylation450 Bead-
chip with 991 participants as described previously (24). The CpG 
sites within the genes containing significantly associated variants 
and the intergenic CpG sites near these genes were examined to 
test whether their methylation levels were associated with lipid levels 
or not by using linear mixed models.
For transcriptional profiling, 100 unrelated GOLDN partici-
pants were selected from the extremes of the BMI distribution. 
RNA was extracted from buffy coats by using the TRIzol method 
(ThermoFisher Scientific, Waltham, MA), and the quality was 
evaluated by using Bioanalyzer (Agilent Technologies, Santa 
Clara, CA). After sequencing and alignment, we fitted linear 
mixed models to test for associations between gene transcript 
level and lipid phenotypes.
RESULTS
Demographic and clinical characteristics
Demographic and clinical characteristics of the study 
subjects are listed in Table 1 and supplemental Table S2. 
From 186 families, we included 435 males and 459 females 
from the GOLDN study. Levels of TG, LDL-C, and HDL-C 
after FFB treatment were significantly different from pre-
treatment levels (P  0.05) (Table 1). As described before 
(25), TG levels increased significantly during the first 3.5 h 
and decreased significantly from 3.5 to 6 h after both high-
fat meals (pre- and post-FFB) (P  0.05). Moreover, the 
post-FFB clearance was significantly different than the pre-FFB 
clearance (P  0.05).
Exome sequencing
On average, 61,235,513 (SD = 11,606,103) reads per 
sample were generated, and 98.9% reads were mapped to 
the reference genome. In total, 968,507 variants (124,661 
exonic variants) were called. The average read depth for 
each sample across the 968,507 variants ranged from 25.5 
to 111.2 (mean = 52.3). After filtering out variants with 
missing rate > 0.05, genotype quality < 30, and read depth 
< 20, a total of 83,577 functional variants were kept, located 
within exonic regions of 16,333 genes on autosomes. Of 
those, 74,216 rare variants with minor allele frequency 
(MAF) < 0.05 were located in 14,795 genes, while 66,605 
rare variants with MAF < 0.01 were located in 14,521 genes. 
Transitions/transversions ratio of SNPs that passed QC was 
2.61, and the heterozygous/homozygous ratio was 1.74. A 
small percentage (2.8%) of these 83,577 variants were in-
cluded in our previous GWAS (8), for which the genotype 
concordance was 98.8%. Across the autosomes, each par-
ticipant had an average of 1 splicing, 4 stop-loss, 23 stop-
gain, and 3,154 nonsynonymous biallelic variants. Rare 
variants (MAF < 0.05) were more enriched in variants of 
greater functional impact (Fig. 1), which may indicate pu-
rifying selection of deleterious alleles (30, 31).
Association tests
By using the Bonferroni correction for multiple testing, 
P < 5.98E-07 (0.05/83,577) was selected as the exome-wide 
significance threshold for the single-variant association 
test, and no single variant was significant by using minimal 
or full models.
For the gene-based burden test, the Bonferroni cor-
rected significance thresholds were defined as P < 3.38E-06 
(0.05/14,795) and 3.44E-06 (0.05/14,521) with MAF 
thresholds of 0.05 and 0.01, respectively. By using full models, 
the rare coding variants in three genes, ITGA7, SIPA1L2, 
and CEP72, were significantly associated with LDL-C fasting 
level response to FFB, pre-FFB postprandial TG AUI, and 
postprandial TG AUI response to FFB, respectively (Table 2, 
Fig. 2). In consideration of the minimally adjusted model, 
only the rare coding variants in ITGA7 and CEP72 were still 
significantly associated with the same traits, while the rare 
coding variants in SIPA1L2 (P = 5.58E-06) did not reach 
the statistical significance threshold. Below, we present re-
sults based on the MAF threshold of 0.01 for the full model 
unless otherwise noted. The severities of rare variant ef-
fects, predicted by PolyPhen2 (32) or SIFT (33), are listed 
in Table 2.
Associations with rare variants from known lipid genes 
from previous GOLDN studies
We also sought to replicate known candidate genes, in-
cluding APOA5 (34), APOE (11), and APOC3 (35), which 
were reported to carry variants significantly associated with 
TABLE 1. Clinical characteristics of samples in GOLDN
Phenotype
Pre-FFB Post-FFB
Mean SD Mean SD
BMI, kg/m2 28.5 5.6 — —
Glucose, mg/dl 101.51 18.74 99.44 19.05
Systolic blood pressure, mmHg 116.08 16.82 — —
Diastolic blood pressure, mmHg 68.57 9.6 — —
HDL, 0 h, log(mg/dl) 3.81 0.27 3.86 0.26
LDL, 0 h, log(mg/dl) 4.78 0.27 4.60 0.31
TG, 0 h, log(mg/dl) 4.75 0.59 4.36 0.52
TG, 3.5 h, log(mg/dl) 5.38 0.57 4.99 0.55
TG, 6 h, log(mg/dl) 5.23 0.70 4.80 0.61
TG uptake, log(mg/(dl*h)) 0.17 0.08 0.17 0.09
TG clearance, log(mg/(dl*h)) 0.06 0.13 0.08 0.13
TG AUI, mg*h/dl 6.71E-04 3.37E-04 6.65E-04 3.16E-04
The values were log-transformed. 
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Fig. 1. Fraction of SNPs with different MAF range within different 
categories. The categories include synonymous, nonsynonymous, 
and loss of function (i.e., splicing, stopgain, and stoploss). The y 
axis indicates the fraction of SNPs with a different MAF range. 
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one or more lipid class in GOLDN (for response pheno-
types), as well as fasting lipids in other studies (21). The 
variants identified in those genes and their P values are 
listed in supplemental Tables S3 and S4. Overall, we report 
that APOA5 and APOE, but not APOC3, showed associa-
tions with one or more GOLDN lipid traits in single-variant 
or gene-based tests. We note that some known mutations in 
these three genes were not identified in our study or were 
filtered out during QC. For example, a known missense 
SNP (rs7412) in APOE was filtered out because of low read-
ing depth.
Replication results
The significant gene SIPA1L2 for TG postprandial AUI 
was tested for association in the HAPI Heart Study. In total, 
seven exonic functional SNPs were identified in this gene 
within the HAPI Heart Study, one of which was shared with 
GOLDN (supplemental Tables S5 and S6). None of the 
seven SNPs in HAPI Heart Study was significant (supple-
mental Table S5). The association of SIPA1L2 with TG 
postprandial AUI in the HAPI Heart Study was not signifi-
cant (P = 0.97) according to a gene-based test, and the 
effect direction was different from that in GOLDN. The 
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FFB treatment protocol was not a part of the HAPI Heart 
study, and thus we could not attempt replication for ITGA7 
or CEP72.
Functional validation results
We examined whether differential methylation at cyto-
sine–guanine dinucleotides (CpGs) within and neighbor-
ing our top gene findings were associated with our lipid 
traits. After Bonferroni correction for multiple testing, no 
methylation of CpG sites within or neighboring those three 
genes was associated with lipid intervention traits.
We also examined the gene transcript level of candidate 
genes using RNA-Seq data of GOLDN. The gene transcript 
level of SIPA1L2 was significantly associated with TG post-
prandial AUI (P  0.05), and the gene transcript level of 
ITGA7 was borderline associated with LDL-C fasting level 
response to FFB (P = 0.07).
DISCUSSION
High-resolution genetic investigations of lipids have fo-
cused only on fasting phenotypes. In this study, we sought 
to elucidate effects of rare genetic variants on lipid re-
sponse to a high-fat meal and FFB treatment using an 
exome-wide sequencing-based association study for the first 
time. Here, we present preliminary evidence of genetic de-
terminants of lipid response to two interventions. Those 
genes include ITGA7, SIPA1L2, and CEP72. The SIPA1L2 
gene transcript level was associated with the TG postpran-
dial response. In addition, we identified associations re-
lated with lipid response to two interventions in candidate 
genes whose common variants were found to be associated 
with baseline lipid phenotypes in previous studies.
We identified three genes with rare coding-sequence 
mutations whose carriers exhibited clinically relevant 
phenotypic differences compared with noncarriers. Previ-
ous studies offer insights into the observed associations. 
For example, common polymorphisms in ITGA2 (an ITGA7 
homolog) were associated with coronary atherosclerosis 
in a candidate gene association study of the Chinese Han 
population (36). Variants in CEP164 and CEP68, which are 
homologs of CEP72, were reported to be associated with 
TG and LDL-C fasting levels (5, 21, 37). Although no study 
has indicated that SIPA1L2 is related to lipid level so far, 
the gene transcript level of SIPA1L2 was significantly associ-
ated with TG postprandial AUI (P  0.05) in the GOLDN 
RNA-Seq study. Overall, rare variants in these genes war-
rant further study in relation to PPL and FFB treatment 
aimed at curbing elevated fasting and postprandial lipid 
levels.
Previous GOLDN candidate gene studies have interro-
gated variants in APOA5, APOE, and APOC3 (11, 34, 35) 
with respect to lipid traits. Although the functions of these 
genes in controlling lipid fasting levels are well known, we 
lack the knowledge of the effects of their mutations on 
lipid level response to interventions. Lai et al. (34) stud-
ied associations between an APOA5 variant (rs3135506, 
chr11:116662407) and baseline TG and TG response to 
FFB, as well as postprandial TG. Our study replicated their 
findings (supplemental Table S3), where APOA5 rare vari-
ant carriers exhibited significantly higher baseline TG and 
lower baseline HDL-C levels (P  0.05) compared with 
noncarriers. After 3 weeks of FFB treatment, reduction of 
TG fasting level in APOA5 rare variant carriers was signifi-
cantly larger than that in noncarriers (P  0.05), and the 
HDL-C response was also higher (34). Our study adds to 
that study by identifying that rs3135506 in APOA5 was also 
associated with TG postprandial clearance slope, a trait not 
previously analyzed. The effects of two APOE variants 
(rs7412 and rs429358) on TG levels has also been exam-
ined in GOLDN (11). Our study further showed rs429358 
in APOE to be associated with baseline LDL-C and LDL-C 
response to FFB. Liu et al. (35) reported that two intronic 
variants in APOC3 were associated with enhanced TG 
response to FFB treatment. Our study did not cover 
those variants, and we did not uncover any exonic APOC3 
variations with allele count greater than two (supplemental 
Tables S3 and S4). rs76353203, a stop-gain variant in APOC3, 
was reported to be associated with decreased baseline TG, 
increased baseline HDL-C, and decreased baseline LDL-C 
in the Amish population (38). In our study, we observed 
Fig. 2. Distribution of residuals for regression of 
phenotypes on their covariates. The diamonds indi-
cate corresponding residual values of rare variant car-
riers. The x axis is the Z score for residuals. The y axis 
is the sample counts.
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consistent directions of this association, but the variant was 
carried by only one sample, and the association was not 
significant. Overall, these results continue to add to the body 
of literature on these important lipid candidate genes.
This study has several limitations. The efficiency of cap-
ture probes varies considerably for exome sequencing 
(supplemental Fig. S1). Thus, the read depths for partial 
SNPs were low, so that they were excluded by the QC pro-
cedure. For example, rs7412, which was known to be associ-
ated with lipid levels, was excluded due to low read depth. 
In addition, participants from the HAPI Heart Study were 
recruited from the Amish community of Lancaster County, 
PA, who are descendants of about 200 original founding 
individuals (facilitating population drift and potential 
enrichment for rare variants) (29), while the GOLDN 
cohort was recruited from families of general European 
ancestry. Thus, external replication of rare variants was 
likely hindered by the private nature of such polymor-
phisms to individual populations. Also, cohorts with phar-
maceutical intervention phenotypes for lipid traits and 
exome sequencing are rare, so proper replication of the 
pharmacogenetic effects is difficult. Moreover, genetic 
variants in introns, UTR regions, and intergene regions 
were not examined in our study, which could contribute to 
the unexplained variance.
CONCLUSION
In our study, novel rare variants in three genes, ITGA7, 
SIPA1L2, and CEP72, associated with lipid response to a 
high-fat meal and/or a 3-week FFB treatment were found. 
Moreover, the gene transcript level of SIPA1L2 was associ-
ated with the postprandial TG AUI. We identified new in-
tervention trait associations within two known candidate 
genes (APOA5 and APOE). In conclusion, we found novel 
genetic variants that contribute to lipid intervention traits 
and revealed potential underlying molecular mechanisms, 
which may inform biomarkers of disease risk and treatment 
targets.
We gratefully acknowledge the studies and participants who 
provided biological samples and data for TOPMed.
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